Notice: This company has been marked as potentially delisted and may not be actively trading. Pluristem Therapeutics (PSTI) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NBRVF Nabriva Therapeutics plcAugust 18, 2023 | seekingalpha.comPluri CEO Issues Shareholder UpdateJuly 25, 2022 | finance.yahoo.comPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 14, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalJuly 13, 2022 | markets.businessinsider.comPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem: Fiscal Q3 Earnings SnapshotMay 10, 2022 | apnews.comPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New PartnershipMarch 28, 2022 | finance.yahoo.comPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialMarch 23, 2022 | seekingalpha.comPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood TransfusionsMarch 23, 2022 | finance.yahoo.comPluristem Therapeutics, Inc. Common Stock (PSTI)March 21, 2022 | nasdaq.comPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint VentureMarch 8, 2022 | finance.yahoo.comPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food PlatformFebruary 24, 2022 | finance.yahoo.comThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?January 12, 2022 | marketwatch.comPluristem Therapeutics (NASDAQ:PSTI) Downgraded to "Hold" at Zacks Investment ResearchZacks Investment Research lowered Pluristem Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday.January 12, 2022 | marketbeat.comIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatJanuary 10, 2022 | msn.comBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food PlatformJanuary 10, 2022 | finance.yahoo.comPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative MeatJanuary 10, 2022 | nasdaq.comPluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food productsJanuary 10, 2022 | seekingalpha.comBiotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food PlatformJanuary 10, 2022 | finance.yahoo.comPluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market MoverDecember 30, 2021 | nasdaq.comPluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTIDecember 29, 2021 | marketwatch.comPluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDSDecember 28, 2021 | finance.yahoo.comPluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy EndpointDecember 27, 2021 | nasdaq.comPluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19December 27, 2021 | finance.yahoo.comPluristem Therapeutics (NASDAQ:PSTI) Raised to "Buy" at Zacks Investment ResearchZacks Investment Research upgraded Pluristem Therapeutics from a "hold" rating to a "buy" rating and set a $2.50 target price for the company in a report on Wednesday.December 15, 2021 | marketbeat.comIs Pluristem Therapeutics (NASDAQ:PSTI) Using Too Much Debt?November 1, 2021 | nasdaq.comWill Pluristem Therapeutics (NASDAQ:PSTI) Spend Its Cash Wisely?September 1, 2021 | finance.yahoo.comIceCure Medical Ltd (ICCM.TA)August 9, 2021 | ca.finance.yahoo.comLongeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDSJuly 29, 2021 | markets.businessinsider.com Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE! 👉 Yes, I Want the Free Report! 👈 PSTI Media Mentions By Week PSTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PSTI News Sentiment▼0.000.62▲Average Medical News Sentiment PSTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PSTI Articles This Week▼00▲PSTI Articles Average Week Get Pluristem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PLX News TNYA News BDTX News CABA News ABOS News XFOR News TARA News EDIT News CRDL News INMB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PSTI) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrading 5-7 Stocks to Profit $1,300 a Day?If you want a straightforward, faster, and potentially more reliable way to trade… Learn this strategy by w...Prosper Trading Academy | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluristem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
